Single Dose Theophylline

Phase 3Small molecule

MMedical College of Wisconsin

Single Dose Theophylline is one of 101 small molecule programs targeting Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

HypothermiaActive, not recruiting

Acute Kidney InjuryActive, not recruiting

LeukemiaPhase 3

Active, not recruiting

HypothermiaPhase 1/Phase 2

Active, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

58 2

Fludara

Sanofi

Phase 3

11 3

Idamycin

Pfizer

Phase 3

10 4

Neoral

Novartis

Phase 3

9 5

Novantrone

Pfizer

Phase 3

8 6

Leukine

Sanofi

Phase 3

7 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

15 8

Rayos

RRoxane Laboratories

Phase 3

14 9

Busulfex

Akero Therapeutics

Phase 3

13 10

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

Acute Kidney Injury

NCT05853601

Clinical

Trials by Indication[1]

Leukemia1 trial

Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)

Completed·MMedical College of Wisconsin·Phase 3·NCT00412360·224 enrolled

Acute Kidney Injury1 trial

Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage

Active, not recruiting·MMedical College of Wisconsin·Preclinical·NCT05853601·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Single Dose Theophylline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Single Dose Theophylline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Single Dose Theophylline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical College of Wisconsin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedical College of Wisconsin

Single Dose Theophylline

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Leukemia1 trial

Acute Kidney Injury1 trial

References

Drug Info

Quick Facts

Related News